Latest Breaking News On - Immuno oncology therapeutic area - Page 1 : comparemela.com

Servier s Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Int

Servier s Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Int
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalPrnewswire servierEric fohlen weillNathan mellorPatrick therasseSusan pandyaServier groupUs food drug administrationServier pharmaceuticalsClinical developmentDrug administrationVice president clinical developmentCancer metabolism global development oncologyLate stageLife cycle management oncology

Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer

Press release content from Business Wire. The AP news staff was not involved in its creation.

New jerseyUnited statesComunidad autonoma de catalunaNadia caussJosep taberneroJudy kay mooreSonia marquesFabio benedettiTaiho pharmaceutical co ltdOtsuka holding co ltdHebron university hospitalWorld health organizationServier groupTaiho oncology incStrategic communicationsInternational agency for research on cancer

Servier announces outcome from the primary analysis of the Phase III SOLSTICE trial assessing LONSURF (trifluridine/tipiracil) + bevacizumab in a 1st line setting for patients with unresectable mCRC non-eligible for intensive therapy

Servier, a global independent pharmaceutical group, announced today that the primary objective (progression free survival) of the Phase III SOLSTICE trial has not been met. SOLSTICE was designed to evaluate

Saint antoineUnited statesFrance generalKostenloser wertpapierhandelThierry andrPatrick therasseSonia marquesTaiho pharmaceutical co ltdServier groupWorld health organisationLate stageLife cycle managementDeputy head oncologyImmuno oncology therapeutic areaProfessor thierry andrSaint antoine hospital